Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Relief Therapeutics Holdings AG

< Previous 1 2 3 Next >
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers RLFTF RLFTY
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Tickers RLFTF RLFTY
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF RLFTY
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Tickers RLFTF RLFTY
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers RLFTF RLFTY
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Tickers RLFTF RLFTY
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF RLFTY
Relief Therapeutics Expands U.S. Commercial Team
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers RLFTF RLFTY
Relief Therapeutics to Participate in Industry and Investor Conferences in May
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF RLFTY
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Tickers ACER RLFTF RLFTY
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF RLFTY
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers ACER RLFTF RLFTY
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Reports Full-Year 2021 Results and Provides Corporate Update
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers RLFTF RLFTY
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.